Summit Cancer Center-Boise Treats Its First Cancer Patients Using the Accuray Radixact™ System

Freestanding Center is First in the Western U.S. to Treat Patients with this "Smart" Radiation Therapy Delivery System with Fully-Integrated Treatment Planning and Data Management Systems

SUNNYVALE, Calif., Aug. 17, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the Summit Cancer Center-Boise announced today that the Center is now treating patients with the Radixact™ Treatment Delivery System, the next generation TomoTherapy® platform. The Radixact System replaced a competitive conventional linear accelerator in the single-vault freestanding facility, reinforcing the System's value as a mainstream radiation therapy device.

The Radixact System provides precise and accurate treatments for more routine radiation therapy indications including skin, central nervous system, breast, head and neck, lung, prostate, gynecologic, and gastrointestinal malignancies, in addition to more complex treatments such as craniospinal and total marrow irradiation. Additionally, Summit Cancer Center-Boise has the ability to perform stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).

"At Summit Cancer Center-Boise our goal is to use innovative technology to provide our patients with the treatment best suited to their needs. This system allows us to provide precise, individualized treatment while sparing normal tissues and maintaining optimal treatment efficacy," said John E. Gamboa, MD, radiation oncologist, medical director of Summit Cancer Center-Boise.

"We are committed to working with Dr. Gamboa to maximize the benefits the new Radixact System provides to his patients," said Lionel Hadjadjeba, Senior Vice President and Chief Commercial Officer at Accuray. "As the recent TomoTherapy System vs RapidArc study published in the Red Journal demonstrated, the technique used to deliver IMRT can have a major impact on patient outcomes. The Radixact System leverages the TomoTherapy platform's unique helical delivery and is equipped with the tools and technology Dr. Gamboa will need to effectively and efficiently treat any cancer case he and his team may encounter, from initial plan delivery to adaptive therapy to complex retreatments."

Radixact System OverviewThe use of radiation as part of cancer treatment is increasing, both during initial treatment and increasingly for re-treatment, so the ability to deliver the correct dose precisely to the tumor is becoming even more important. The Radixact System was designed to deliver image-guided intensity-modulated radiation therapy, an extremely precise form of radiation therapy.

  • The System is built on a ring gantry platform with a CT scanner. It provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles, ensuring the most precise treatment customized for each patient, minimizing exposure to healthy tissue and measurably mitigating side effects.
  • Treatment accuracy is achieved through daily 3D image guidance which ensures proper patient positioning and dose targeting even when anatomical changes occur. The system takes an image of the patient every day as part of the patient setup, enabling the clinical team to know exactly where the tumor is on that particular day.
  • The ultra-fast binary multileaf collimator, or MLC, is a key component of the System, enabling the System to deliver dose with extremely high precision and accuracy.
  • Continuous couch motion through the bore of the ring gantry facilitates seamless delivery to multiple targets or long volumes with no need for field matching, which would be required if using a conventional delivery device. This innovation in workflow also improves treatment quality by ensuring that highly-sculpted radiation doses can be delivered to tumors located anywhere in the body, regardless of the tumor size or the number of tumors receiving treatment.
  • A fully-integrated, simplified adaptive treatment planning solution, PreciseART™ Adaptive Radiation Therapy software, enables the clinical team to adjust therapy to changes in tumor size, shape and location — as well as subtle changes in the location of organs and other healthy tissue.
  • The PreciseRTX™ Retreatment Option makes it easier for clinicians to deliver precise doses of radiation in those cases where, unfortunately, cancer has recurred and retreatment with radiation is necessary.

Important Safety InformationFor Important Safety Information please refer to

About AccurayAccuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit

Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to advantages of new technology, clinical applications, clinical results, successful adoption of new technologies, patient experiences and outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Investor Contact:Doug SherkEVC Group+1 (646) 445-4800

Media Contacts:Beth KaplanAccuray+1 (408)

Jane HauserMSL Group+1 (781)


View original content with multimedia:
SOURCE Accuray Incorporated